½ÃÀ庸°í¼­
»óǰÄÚµå
1699059

¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå ¼ºÀå, ±Ô¸ð, µ¿Ç⠺м® : Á¦Ç°º°, ¿ëµµº°, Ä¡·áº°, ¸ðµåº° - Áö¿ªº° Àü¸Á, °æÀï Àü·«, ºÎ¹® ¿¹Ãø(-2034³â)

Outpatient Oncology Infusion Market Growth, Size, Trends Analysis - By Product, By Application, By Therapy, By Mode - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SPER Market Research Pvt. Ltd. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 260 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Àü ¼¼°è ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 10.86%ÀÇ CAGRÀ» ±â·ÏÇϸç 74¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿Ü·¡ Á¾¾ç ÁÖÀÔÀ̶õ ¸é¿ª¿ä¹ý, È­Çпä¹ý, Ç¥ÀûÄ¡·á µîÀÇ ¾Ï Ä¡·á¸¦ ÀÔ¿øÇÏÁö ¾Ê°í ¿Ü·¡¿¡¼­ ½ÃÇàÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ȯÀڴ Ŭ¸®´Ð, ¿Ü·¡ Áø·á ¼¾ÅÍ ¶Ç´Â ¼ö¾× Àü¹® ¼¾ÅÍ¿¡¼­ ÀÇÇÐÀû °ü¸® ÇÏ¿¡ ¼ö¾× Ä¡·á¸¦ ¹Þ°Ô µË´Ï´Ù. ÀÌ Àü·«Àº ¾ÈÀüÇϰí È¿À²ÀûÀÎ Ä¡·á¸¦ º¸ÀåÇÏ´Â µ¿½Ã¿¡ ȯÀÚÀÇ ÆíÀǼºÀ» °³¼±Çϰí ÀÇ·áºñ¸¦ Àý°¨Çϸç ÀÔ¿ø ±â°£À» ´ÜÃàÇÕ´Ï´Ù.

°í°¡ÀÇ Ä¡·áºñ, º¹ÀâÇÑ »óȯ ÀýÂ÷, ȯÀÚÀÇ °æÁ¦Àû Á¦¾à µîÀÌ ½ÃÀåÀÌ Á÷¸éÇÑ °úÁ¦ Áß ÀϺÎÀÔ´Ï´Ù. ¾Ï Àü¹® °£È£»ç¿Í ¾à»çÀÇ ºÎÁ·Àº ¼­ºñ½º Á¦°øÀ» ´õ¿í ¾î·Æ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿Ü·¡ ȯÀÚÀÇ ¾à¹° ºÎÀÛ¿ëÀ» ¾ïÁ¦Çϰí ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇϱâ À§Çؼ­´Â ¾ö°ÝÇÑ ÀýÂ÷¿Í ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÕ´Ï´Ù.

¼¼°èÀÇ ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¿µÇâ¿äÀÎ ¹× ½ÃÀå ±âȸ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÁ¤°ú ¿¹Ãø, °¢Á¾ ºÎ¹®º°¡¤Áö¿ªº°¡¤ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ, Á¦¾à¿äÀÎ, ±âȸ ¿äÀÎ, °úÁ¦ ºÐ¼®

Á¦5Àå ½ÃÀå º¯¼ö¿Í Àü¸Á

  • SWOT ºÐ¼®
  • PESTEL ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • È÷Æ®¸Ê ºÐ¼®

Á¦6Àå °æÀï ±¸µµ

  • Á¦Á¶ °ÅÁ¡ ºÐÆ÷¡¤ÆÇ¸Å Áö¿ª¡¤Á¦Ç° À¯Çü
  • M&A¡¤Á¦ÈÞ¡¤Á¦Ç° ¹ß¸Å¡¤Çù·Â

Á¦7Àå ¼¼°èÀÇ ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå : Á¦Ç°º°

  • ÁÖÀÔ ÆßÇÁ
  • Á¤¸ÆÁÖ»ç ¼¼Æ®
  • IV ij´¼¶ó
  • ´Ïµé¸®½º Ä¿³ØÅÍ

Á¦8Àå ¼¼°èÀÇ ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå : ¿ëµµº°

  • Æó¾Ï
  • °£¾Ï
  • À¯¹æ¾Ï
  • Àü¸³¼±¾Ï

Á¦9Àå ¼¼°èÀÇ ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå : Ä¡·á¹ýº°

  • È­Çпä¹ý
  • Ç¥Àû¿ä¹ý
  • ¸é¿ª¿ä¹ý
  • È£¸£¸ó¿ä¹ý

Á¦10Àå ¼¼°èÀÇ ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå : ¸ðµåº°

  • ±ÙÀ°³»(IM)
  • Á¤¸Æ³»(IV)
  • ÇÇÇÏ

Á¦11Àå ¼¼°èÀÇ ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå

  • ¼¼°èÀÇ ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå ±Ô¸ð¿Í ½ÃÀå Á¡À¯À²

Á¦12Àå ¼¼°èÀÇ ¿Ü·¡ Á¾¾ç ÁÖÀÔ ½ÃÀå : Áö¿ªº°

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ
  • À¯·´
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ¿µ±¹
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • UAE
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ÀÌÁýÆ®
    • ¸ð·ÎÄÚ
    • ³ªÀÌÁö¸®¾Æ
    • ±âŸ
  • ºÏ¹Ì
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
    • ¹Ì±¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ±âŸ

Á¦13Àå ±â¾÷ °³¿ä

  • B. Braun Melsungen AG
  • Baxter
  • Becton, Dickinson, and Company
  • Fresenius Kabi
  • ICU Medical, Inc
  • IRadimed Corporation
  • Medtronic PLC
  • Micrel Medical Devices SA
  • Moog, Inc.
  • Nipro Corporation
  • ±âŸ

Á¦14Àå °á·Ð

Á¦15Àå ¾à¾î ¸®½ºÆ®

Á¦16Àå Âü°í ¸µÅ©

ksm 25.04.22

Outpatient Oncology Infusion Market Introduction and Overview

According to SPER market research, 'Global Outpatient Oncology Infusion Market Size- By Product, By Application, By Therapy, By Mode - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Outpatient Oncology Infusion Market is predicted to reach 7.46 billion by 2034 with a CAGR of 10.86%.

Outpatient oncology infusion represents the delivery of cancer treatments, such as immunotherapy, chemotherapy, or targeted therapy, in an outpatient setting without the need for hospital. Patients get intravenous drugs under medical supervision at clinics, ambulatory care centres, or specialist infusion centres. While ensuring safe and efficient treatment, this strategy improves patient convenience, lowers medical costs, and shortens hospital stays.

Restraints: High treatment costs, complicated reimbursement procedures, and patient financial constraints are some of the issues facing the outpatient oncology infusion business. Service delivery is further strained by a lack of qualified oncology nurses and pharmacists. Strict procedures and oversight are also necessary for controlling adverse medication responses and guaranteeing patient safety in outpatient settings.

Scope of the Report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Product, By Application, By Therapy, By Mode.

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa.

Companies Covered

      • B. Braun Melsungen AG, Baxter, Becton, Dickinson, and Company, Fresenius Kabi, ICU Medical, Inc, IRadimed Corporation, Medtronic PLC, Micrel Medical Devices SA, Moog, Inc., Nipro Corporation. and others.

Outpatient Oncology Infusion Market Segmentation:

By Product: Based on the Product, Global Outpatient Oncology Infusion Market is segmented as; Infusion pumps, Intravenous sets, IV cannulas, Needleless connectors.

By Application: Based on the Application, Global Outpatient Oncology Infusion Market is segmented as; Lung cancer, Liver cancer, Breast cancer, Prostate cancer.

By Therapy: Based on the Therapy, Global Outpatient Oncology Infusion Market is segmented as; Chemotherapy, Targeted therapy, Immunotherapy, Hormonal therapy.

By Mode: Based on the Mode, Global Outpatient Oncology Infusion Market is segmented as; Intramuscular (IM), Intravenous (IV), Subcutaneous.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe and Middle East & Africa.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPERs internal database
    • 2.1.4. Premium insight from KOLs
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTERs Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Outpatient Oncology Infusion Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Outpatient Oncology Infusion Market

7. Global Outpatient Oncology Infusion Market, By Product (USD Million) 2021-2034

  • 7.1. Infusion pumps
  • 7.2. Intravenous sets
  • 7.3. IV cannulas
  • 7.4. Needleless connectors

8. Global Outpatient Oncology Infusion Market, By Application (USD Million) 2021-2034

  • 8.1. Lung cancer
  • 8.2. Liver cancer
  • 8.3. Breast cancer
  • 8.4. Prostate cancer

9. Global Outpatient Oncology Infusion Market, By Therapy (USD Million) 2021-2034

  • 9.1. Chemotherapy
  • 9.2. Targeted therapy
  • 9.3. Immunotherapy
  • 9.4. Hormonal therapy

10. Global Outpatient Oncology Infusion Market, By Mode (USD Million) 2021-2034

  • 10.1. Intramuscular (IM)
  • 10.2. Intravenous (IV)
  • 10.3. Subcutaneous

11. Global Outpatient Oncology Infusion Market, (USD Million) 2021-2034

  • 11.1. Global Outpatient Oncology Infusion Market Size and Market Share

12. Global Outpatient Oncology Infusion Market, By Region, (USD Million) 2021-2034

  • 12.1. Asia-Pacific
    • 12.1.1. Australia
    • 12.1.2. China
    • 12.1.3. India
    • 12.1.4. Japan
    • 12.1.5. South Korea
    • 12.1.6. Rest of Asia-Pacific
  • 12.2. Europe
    • 12.2.1. France
    • 12.2.2. Germany
    • 12.2.3. Italy
    • 12.2.4. Spain
    • 12.2.5. United Kingdom
    • 12.2.6. Rest of Europe
  • 12.3. Middle East and Africa
    • 12.3.1. Kingdom of Saudi Arabia
    • 12.3.2. United Arab Emirates
    • 12.3.3. Qatar
    • 12.3.4. South Africa
    • 12.3.5. Egypt
    • 12.3.6. Morocco
    • 12.3.7. Nigeria
    • 12.3.8. Rest of Middle-East and Africa
  • 12.4. North America
    • 12.4.1. Canada
    • 12.4.2. Mexico
    • 12.4.3. United States
  • 12.5. Latin America
    • 12.5.1. Argentina
    • 12.5.2. Brazil
    • 12.5.3. Rest of Latin America

13. Company Profile

  • 13.1. B. Braun Melsungen AG
    • 13.1.1. Company details
    • 13.1.2. Financial outlook
    • 13.1.3. Product summary
    • 13.1.4. Recent developments
  • 13.2. Baxter
    • 13.2.1. Company details
    • 13.2.2. Financial outlook
    • 13.2.3. Product summary
    • 13.2.4. Recent developments
  • 13.3. Becton, Dickinson, and Company
    • 13.3.1. Company details
    • 13.3.2. Financial outlook
    • 13.3.3. Product summary
    • 13.3.4. Recent developments
  • 13.4. Fresenius Kabi
    • 13.4.1. Company details
    • 13.4.2. Financial outlook
    • 13.4.3. Product summary
    • 13.4.4. Recent developments
  • 13.5. ICU Medical, Inc
    • 13.5.1. Company details
    • 13.5.2. Financial outlook
    • 13.5.3. Product summary
    • 13.5.4. Recent developments
  • 13.6. IRadimed Corporation
    • 13.6.1. Company details
    • 13.6.2. Financial outlook
    • 13.6.3. Product summary
    • 13.6.4. Recent developments
  • 13.7. Medtronic PLC
    • 13.7.1. Company details
    • 13.7.2. Financial outlook
    • 13.7.3. Product summary
    • 13.7.4. Recent developments
  • 13.8. Micrel Medical Devices SA
    • 13.8.1. Company details
    • 13.8.2. Financial outlook
    • 13.8.3. Product summary
    • 13.8.4. Recent developments
  • 13.9. Moog, Inc.
    • 13.9.1. Company details
    • 13.9.2. Financial outlook
    • 13.9.3. Product summary
    • 13.9.4. Recent developments
  • 13.10. Nipro Corporation
    • 13.10.1. Company details
    • 13.10.2. Financial outlook
    • 13.10.3. Product summary
    • 13.10.4. Recent developments
  • 13.11. Others

14. Conclusion

15. List of Abbreviations

16. Reference Links

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦